Use of the nicotine metabolite ratio as a genetically informed biomarker of response to nicotine patch or varenicline for smoking cessation: a randomised, double-blind placebo-controlled trial.
about
Transdisciplinary translational behavioral (TDTB) research: opportunities, barriers, and innovationsSmoking cessation and the cardiovascular patientThe Past, Present, and Future of Nicotine Addiction TherapyDrug Metabolizing Enzyme and Transporter Gene Variation, Nicotine Metabolism, Prospective Abstinence, and Cigarette ConsumptionResting-state functional connectivity and nicotine addiction: prospects for biomarker developmentExamination of the mechanism of action of two pre-quit pharmacotherapies for smoking cessation.Predictors of Variation in CYP2A6 mRNA, Protein, and Enzyme Activity in a Human Liver Bank: Influence of Genetic and Nongenetic Factors.What Does "Precision Medicine" Have to Say About Prevention?Precision Medicine for Tobacco Dependence: Development and Validation of the Nicotine Metabolite RatioPathways to precision medicine in smoking cessation treatments.Pharmacogenetic Optimization of Smoking Cessation Treatment.Lack of Associations of CHRNA5-A3-B4 Genetic Variants with Smoking Cessation Treatment Outcomes in Caucasian Smokers despite Associations with Baseline SmokingBiomarkers of Response to Smoking Cessation Pharmacotherapies: Progress to Date.A Genome-Wide Association Study of a Biomarker of Nicotine Metabolism.Smokescreen: a targeted genotyping array for addiction researchRate of nicotine metabolism and smoking cessation outcomes in a community-based sample of treatment-seeking smokers.Decreased Nicotinic Receptor Availability in Smokers with Slow Rates of Nicotine MetabolismLeveraging genomic data in smoking cessation trials in the era of Precision Medicine: Why and how.A public health perspective on a national precision medicine cohort: balancing long-term knowledge generation with early health benefitA clinical trial to examine disparities in quitting between African-American and White adult smokers: Design, accrual, and baseline characteristics.Varenicline-Induced Elevation of Dopamine in Smokers: A Preliminary [(11)C]-(+)-PHNO PET Study.Cessation of alcohol consumption decreases rate of nicotine metabolism in male alcohol-dependent smokersDisposition kinetics and metabolism of nicotine and cotinine in African American smokers: impact of CYP2A6 genetic variation and enzymatic activityA prospective and retrospective analysis of smoking behavior changes in ever smokers with high risk for lung cancer from New Mexico and Pennsylvania.Genome-Wide Association of the Laboratory-Based Nicotine Metabolite Ratio in Three Ancestries.Effects of aging on the effectiveness of smoking cessation medication.Nicotine Replacement Therapy as a Maintenance Treatment.Nicotine biomarkers and rate of nicotine metabolism among cigarette smokers taking buprenorphine for opioid dependency.Sleep Disturbance During Smoking Cessation: Withdrawal or Side Effect of Treatment?Does cannabis use moderate smoking cessation outcomes in treatment-seeking tobacco smokers? Analysis from a large multi-center trial.Nicotine Dependence and Urinary Nicotine, Cotinine and Hydroxycotinine Levels in Daily Smokers.CYP2A6 Genetic Variation Alters Striatal-Cingulate Circuits, Network Hubs, and Executive Processing in Smokers.The Value of Biosamples in Smoking Cessation Trials: A Review of Genetic, Metabolomic, and Epigenetic Findings.The use of varenicline to treat nicotine dependence among patients with cancer.Racial differences in the relationship between rate of nicotine metabolism and nicotine intake from cigarette smoking.Measures and predictors of varenicline adherence in the treatment of nicotine dependence.Sex Differences in Varenicline Efficacy for Smoking Cessation: A Meta-Analysis.Sex Differences in Smoking Cessation Pharmacotherapy Comparative Efficacy: A Network Meta-analysis.Perceptions of pharmacogenetic research to guide tobacco cessation by patients, providers and leaders in a tribal healthcare setting.CYP2A6 genotyping methods and strategies using real-time and end point PCR platforms.
P2860
Q26751401-1F9CB44D-DAC2-41BC-9F60-8014D37809E0Q28082695-08E950C1-0E86-4324-929C-BBFB5475E51AQ28088508-A37B7859-44DF-4337-9333-3550D9A6569BQ28397614-1925B611-A12D-456E-96C3-7FA9307D1405Q30992161-C735D8E1-D46A-4D05-85AC-A8AE7ACEE8E7Q33446364-218F0448-CCAC-4FB0-BBE3-800FC2763B24Q33458739-88413A85-4A93-4426-8E31-1833FAF76D5EQ33752543-37E3E3F6-2607-483D-B9A2-CB23031E9B17Q33821233-5AC04F88-2443-49CD-879A-FAFBC12706E8Q34527740-84F7AAD9-36DB-49D4-B7DB-A06442F10C08Q34542169-5D49DE0C-B2B4-4EBE-9255-BFDA5EC207DEQ35641707-54C44313-462F-4B4F-B4BE-5659594A10A7Q35751986-3668A887-5D89-41DE-AF41-631FC72D3949Q35788753-2EFFA2CD-369E-4068-8FB5-A1A4578017D0Q35938102-922138AB-79DB-477D-B597-716E91948F15Q36021256-D4EA6810-1367-48FD-B877-691E8281214BQ36283969-FBD4E718-37A3-49CF-9647-7F778270C583Q36370325-7EE4890C-047C-4521-83ED-6D63EDEAE8E0Q36388922-0B1199ED-5DB7-47A4-9D27-2EA6C6756770Q36757788-D4F76649-8A3B-48BD-A82C-034E1D119BC1Q36798993-9BE1CD6D-35E5-4D06-8184-F3B7E9A9B6E5Q36936189-03562BDB-6FBD-4FB6-BDD7-F7CD66821F2CQ36968374-4A286DF9-7A48-410D-B189-1F0338C82B37Q37019196-A5C9963B-48C8-4503-9188-B1BDF4DDFDD0Q37163230-20EED165-92BC-42BC-B05F-2CCC1AD0C5B1Q37327407-ECE044D3-2760-4644-A0C4-587C0BD76934Q37461492-E25A9AEE-9BAD-4EDB-9166-F48511276256Q38661924-F7356DEC-C555-4B21-A565-F46EB27324D6Q38758931-2BB49D5F-0C47-473A-8F2A-821D26D32B6DQ38866239-61E596D6-7BAC-45E5-AB5E-26F5FE998920Q38880696-AF98DFA0-A6A5-479E-92F1-BC56EBF13746Q39172105-6303ABCA-1FA3-4A2C-9EE3-B533296BA548Q39284073-EE225314-A984-4371-92A0-3913ED46B072Q39740632-A1E11F69-3AB9-48C4-83CA-C8C9BF9D9875Q39765572-DE2F47B4-43AD-43B1-9E54-97DEE5D82728Q40114814-AB4FBB42-12FD-4462-ABB7-E87189565402Q40456297-0EE73167-A621-42A2-B3D3-4BEC385E2DB7Q40587312-C7F9EC23-74FB-41BC-8236-9A6B523581D8Q41430010-18C7F310-99D7-4FE7-BFCA-C8D31E7C005FQ41927477-450CD82F-D759-4D78-AF8E-2849F21A1D2F
P2860
Use of the nicotine metabolite ratio as a genetically informed biomarker of response to nicotine patch or varenicline for smoking cessation: a randomised, double-blind placebo-controlled trial.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Use of the nicotine metabolite ...... lind placebo-controlled trial.
@ast
Use of the nicotine metabolite ...... lind placebo-controlled trial.
@en
type
label
Use of the nicotine metabolite ...... lind placebo-controlled trial.
@ast
Use of the nicotine metabolite ...... lind placebo-controlled trial.
@en
prefLabel
Use of the nicotine metabolite ...... lind placebo-controlled trial.
@ast
Use of the nicotine metabolite ...... lind placebo-controlled trial.
@en
P2093
P2860
P921
P1476
Use of the nicotine metabolite ...... lind placebo-controlled trial.
@en
P2093
Caryn Lerman
Daniel F Heitjan
E Paul Wileyto
Gary E Swan
Neal L Benowitz
PGRN-PNAT Research Group
Paul Cinciripini
Robert A Schnoll
Tony P George
P2860
P304
P356
10.1016/S2213-2600(14)70294-2
P577
2015-01-12T00:00:00Z